SLNO
Soleno Therapeutics, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
101.53
PEG
0.91
P/B
6.17
P/S
14.74
EV/EBITDA
96.50
DCF Value
$169.01
FCF Yield
1.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
98.6%
Operating Margin
5.4%
Net Margin
11.0%
ROE
5.9%
ROA
3.7%
ROIC
2.0%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $91.7M | $43.4M | $0.80 |
| FY 2025 | $190.4M | $20.9M | $0.39 |
| Q3 2025 | $66.0M | $26.0M | $0.47 |
| Q2 2025 | $32.7M | $-4.7M | $-0.09 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllLatest News
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
-2.81
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.